drugset
drugset / Trial / NCT04077255

EGFR-targeted Therapy for Gastric Cancer

NCT04077255 ↗

Phase 2 Unknown 19 enrolled National Cancer Center, Korea Korean Cancer Study Group · collab
NaSingle-groupOpen-labelTreatment

Summary

Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.

Timeline

Start
2019-09-01
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GC1118 Monoclonal antibody — Intravenous
Background Paclitaxel Small molecule — —

Indications

gastric adenocarcinoma